Skip to content
2000
Volume 3, Issue 3
  • ISSN: 1574-8928
  • E-ISSN: 2212-3970

Abstract

There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/157489208786242287
2008-11-01
2025-09-23

  • From This Site

    /content/journals/pra/10.2174/157489208786242287
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/content/journals/pra/10.2174/157489208786242287
Loading

  • Article Type:     Research Article
Keyword(s): antithrombotic agents; antitumor therapy; Low molecular weight heparins (LMWH); venous thromboembolism (VTE)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test